Cambridge Healthtech Institute’s Second Annual

Strategic and Operational Challenges of Oncology & Immuno-Oncology Drug Development

Responding to the New Reality and Pace of Immuno-Oncology and Immunotherapy Projects and Trials

October 14-15, 2019


CHI-logo-color&     Pharmica-Logo


In partnership with Pharmica Consulting, we invite you to attend CHI’s and the BioPharma Strategy Series’ 2nd Annual Strategic and Operational Challenges of Oncology and Immuno-Oncology Drug Development conference being held October 14-15, 2019 at The Bellevue Hotel in Philadelphia, PA.

 

Each new cancer diagnosis underscores the importance of delivering new therapies to patients. The biopharmaceutical industry is investing resources in developing new treatments, but the timelines are long and the costs very high. In addition, the pathway for development is unclear and the rapidity of new approvals is highly impactful to programs in process…and benchmarks are constantly changing! To optimize development of new oncology and immuno-oncology treatments for cancer, we must shorten the time of development, while reducing the overall costs and the number of failed attempts. We need to be smarter and more innovative about how we execute oncology studies. For program managers and TA heads, is there an efficient way to get to decisions faster? With no clear pathway for development, the program managers, project managers and clinical trial leaders in the biopharma industry who must ferry these long, complicated programs through all phases and, ideally, to market, play a critical role at the intersection of science, business and operations. Join your colleagues to learn about the latest drug development and project management challenges across the oncology, immuno-oncology and immunotherapy combinations value chain and how to navigate what has become the most research-intensive therapeutic area in drug development. Hear from others on what being successful in this challenging arena requires.

DRIVING INNOVATION IN ONCOLOGY AND IO DRUG DEVELOPMENT

The State of Oncology and Immuno-Oncology: An Overview

Matt Kiernan, Partner, Pharmica Consulting

The Key Components of Driving Innovation in Drug Development: Culture and Governance

Courtland R. LaVallee, Head, Immuno-oncology Program Management, Program Management, BeiGene USA

CO-PRESENTATION: Optimizing Governance for a Growing Organization

Jane Moon, MBA, PMP, Senior Manager, CMC Performance and Analytics, Kite Pharma, a Gilead Company

Anup Patel, MPH, Senior Manager, CMC Engagement, Kite Pharma, a Gilead Company

PANEL DISCUSSION: Investing in Oncology and IO: Perspectives from Venture Capitalists and Pharma Ventures

Stephen Curtis, PhD, Principal, MPM Capital

Michael Baran, Executive Director, WRD, Principal, Pfizer Ventures

DRIVING ONCOLOGY AND IO IN A COLLABORATIVE ECOSYSTEM

PANEL DISCUSSION: Clinical Collaborations between Pharma and Biotech for Combination Drugs in IO

Nathan Sanburn, Senior Advisor, Global Business Development and Strategic Collaborations, Oncology Business Unit, Eli Lilly

IMPROVING CLINICAL TRIALS: TECHNOLOGIES AND ANALYTICS

Utilizing Technologies in IO Operations

Dan Tierno, Associate Director, Global Clinical Data Sciences and Analytics, Bayer

Improving Clinical Trials through Performance Analytics

Peter Malamis, CCO, ImmunoRestoration, Inc.


 

For more details on the conference, please contact:

Kaitlin Searfoss Kelleher

Conference Producer

Cambridge Healthtech Institute

Phone: (+1) 781-972-5498

Email: kkelleher@healthtech.com

 

For partnering and sponsorship information, please contact:
Katelin Fitzgerald

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5458

Email: kfitzgerald@healthtech.com


Register Today!

For questions about this year's event, please contact:

Kaitlin Searfoss Kelleher
Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5498
E: kkelleher@healthtech.com